Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -36.00 -2.68% 1,309.00 1,302.00 1,304.00 1,350.00 1,287.00 1,350.00 562,921 16:35:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 259.9 56.4 22.0 59.5 2,691

ABCAM PLC Annual Financial Report

30/09/2019 1:35pm

UK Regulatory (RNS & others)

Abcam (LSE:ABC)
Historical Stock Chart

2 Months : From Sep 2019 to Nov 2019

Click Here for more Abcam Charts.


RNS Number : 1836O


30 September 2019

30 September 2019


("Abcam" or "the Company")

Publication of 2019 Annual Report and Accounts

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that its Annual Report and Accounts for the year ended 30 June 2019 will be published today on the Company's investor relations website,

It will also be posted today, together with the Notice of Annual General Meeting, to those shareholders that have elected to receive paper communications. Shareholders that have not elected to receive paper communications will be notified of the availability of these documents on the Company's investor relations website,

For further information please contact:

Abcam plc                                            + 44 (0) 1223 696 000 
Marc Perkins, Company Secretary 
 James Staveley, Vice President Investor Relations 

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Group offers highly validated antibodies and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Some two-thirds of the world's 750,000 life science researchers use Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Group continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 140 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

Please visit or to find out more.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

September 30, 2019 08:35 ET (12:35 GMT)

1 Year Abcam Chart

1 Year Abcam Chart

1 Month Abcam Chart

1 Month Abcam Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191119 20:36:00